Astellas Pharma announced it is acquiring Ocata Therapeutics for $379M. Headquartered in Tokyo, Japan, Astellas is the second largest drug company in Japan, generating over $10 billion in drug sales last year, while Ocata is headquartered in Marlborough, Massachusetts. Astellas’ cash flow is essential, because the company has agreed to pay $8.50 a share for Ocata, a 79% premium over the stock price last Friday. [Read more…]
Consolidation Continues within the Cord Blood Market – AlphaCord Acquires LifeSource Cryobank
Today, AlphaCord released the major news that it is acquiring LifeSource Cryobank. This merger continues the trend of consolidation within the global cord blood banking market. It also continues AlphaCord’s trend of consolidation, as this was its fifth acquisition of smaller cord blood banks.
Earlier this year, on June 29, 2015, the largest cord blood bank in the United States and the world, Cord Blood Registry® (CBR®) announced that it had entered into a definitive agreement to be acquired by AMAG Pharmaceuticals, a company based out of Based in Waltham, Massachusetts. The value of the deal was set at $700 million, which established value of over 5.55 times revenue and over 15.55 times EBITDA. [Read more…]
3 Bullet Thursday – Astellas Acquires Ocata, CDI Partners with Roche, and iPSC Trial for Parkinson’s Delayed
Stay alert to the latest and greatest on stem cells. Enjoy this week’s “3 Bullet Thursday,” a weekly post that we do to update you on interesting and important events within the world of stem cells.
1. In major news this week, Astellas Pharma announced it is acquiring Ocata Therapeutics for $379M. Astellas, a major drug company in Japan, will pay $8.50 a share, a 79% premium over the stock price last Friday. Ocata, which changed its name from Advanced Cell Technology last November, specializes in using pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), to treat diseases of the eye. [Read more…]
Cynata Partners with Harvard University and University of Sydney
In a recent “Activity Report” released by Cynata Therapeutics, the company announced the status of key business activities and partnerships, including a recent collaboration with Harvard Medical School to treat cancer using toxin-secreting stem cells. It has also entered into a collaboration with the University of Sydney that will address myocardial infarction using the therapeutic properties Cynata’s iPSC-derived mesenchymal stem cells (MSCs).
In addition, the company recently announced that their Cymerus™ derived MSCs will be utilized in a clinical trial for GvHD, the first in-patient test of the company’s novel stem cell manufacturing process.
These activities are resulting from Cynata’s proprietary manufacturing platform that can produce unlimited quantities of mesenchymal stem cells (MSCs) by deriving them from induced pluripotent stem cells (iPSCs) produced from a single donor. This Cymerus™ technology has made Cynata one of the first commercial providers to achieve consistent, scalable, and importantly, cost-effective production of clinical-grade stem cells. The company’s novel manufacturing approach is overcoming a major hurdle that has traditionally limited the therapeutic use of stem cells, which is the “sky high costs” associated with such procedures. [Read more…]
3D Printing, Stem Cell Manufacturing, Future Directions for iPSCs, and More
Hey, we’ve posted new content about stem cells and cord blood that I’m excited to share with you. Let me know what you think.
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news by announcing that mesenchymal stem cells produced using its Cymerus™ manufacturing platform will be utilized in a Phase 1 clinical study involving patients with steroid-refractory GvHD. The Clinical Trial Company Ltd was identified as the contract research organization (CRO) that Cynata has engaged to conduct the study.
In a July 2013 USA Today article, Rem Rieder discusses how Twitter “can function as a conveyor belt for first-rate journalism, bringing to your attention terrific material that you might otherwise never encounter”. He then goes on to point out that Twitter is a news pipeline for more than 200 million active users, often ‘breaking’ news before it’s actually news. In this article, you’ll learn the top 15 accounts to follow on Twitter to have breaking stem cell news delivered to your Twitter feed.
The discovery that we can induce plasticity in formerly fully differentiated cells is one of the greatest inventions of the last decades. In this article, Kevin Bielec, a Scientist at RheinCell Therapeutics GmbH, explores a several aspects that should be considered as future directions for iPSC-related research and development. RheinCell is a Düsseldorf-based company that specializes in research-grade production and characterization of human induced pluripotent stem cells (iPSC).
Click here to view all recently released blog posts or here to view BioInformant’s global strategic reports for the stem cell and cord blood industry. Be great!
- « Previous Page
- 1
- …
- 292
- 293
- 294
- 295
- 296
- …
- 314
- Next Page »